Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today the launch of an innovative age-based test
protocol that aids physicians when ordering cervical cancer and sexually
transmitted disease (STD) screening tests.
Through this age-based approach, clinicians can select a test number
that will individualize cervical cancer and STD testing based on patient
age (from 21-64) and the corresponding age-based test protocol - as set
forth in the American Congress of Obstetricians and Gynecologists (ACOG)
guidelines.
"This is a novel approach," said Dr. Mark Brecher, LabCorp's Chief
Medical Officer. "Offering cervical cancer testing and STD alternatives
that follow the ACOG guidelines for age-based testing provides our
clients an important tool to assist in providing the best possible
patient care."
This enhancement to LabCorp's test menu is an adjunct to its broad
women's health test options, including tests that focus on both
screening and diagnosis of disease. In addition to its women's health
services, LabCorp offers a comprehensive menu of individual tests and
test combinations to address specific patient needs.